PET/CT for therapy response assessment in lymphoma.

  title={PET/CT for therapy response assessment in lymphoma.},
  author={Martin Hutchings and Sally F Barrington},
  journal={Journal of nuclear medicine : official publication, Society of Nuclear Medicine},
  volume={50 Suppl 1},
PET with (18)F-FDG is a standard staging procedure for most lymphoma subtypes. Performed during and after therapy for Hodgkin lymphoma (HL) and aggressive non-Hodgkin lymphoma (NHL), (18)F-FDG PET results have a high prognostic value and correlate with survival. (18)F-FDG PET has been incorporated into revised response criteria for aggressive lymphomas, and several ongoing trials are under way to investigate the value of treatment adaptation based on early (18)F-FDG PET results for HL and… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS
66 Citations
78 References
Similar Papers


Publications citing this paper.
Showing 1-10 of 66 extracted citations


Publications referenced by this paper.
Showing 1-10 of 78 references

18-PET/CT imaging in assessing response to chemotherapy in patients with newly diagnosed stage II, stage III, or stage IV Hodgkin lymphoma

  • F Fludeoxyglucose
  • 2009
3 Excerpts

Combined ESCBEACOPP-ABVD therapy for advanced Hodgkin’s lymphoma patients with high IPS score: an effective regimen and low positive predictive value of early FDG-PET/CT [abstract

  • A Avigdor, S Bulvik, EJ Dann
  • Haematologica
  • 2007
1 Excerpt

Early interim FDG-PET during intensified BEACOPP therapy shows a lower predictive value than during conventional ABVD chemotherapy

  • A Gallamini, S Viviani, V Bonfante
  • [abstract]. Haematologica
  • 2007
1 Excerpt

Similar Papers

Loading similar papers…